New Zealand markets close in 3 hours 30 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.1000+0.0500 (+2.44%)
At close: 04:00PM EDT
2.1500 +0.05 (+2.38%)
After hours: 05:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0500
Open2.0000
Bid1.9000 x 800
Ask2.1600 x 3200
Day's range2.0000 - 2.1400
52-week range1.2500 - 8.5900
Volume51,267
Avg. volume159,404
Market cap49.335M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.8860
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.17
  • Business Wire

    Spruce Biosciences to Participate in June Investor Conferences

    SAN FRANCISCO, June 01, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June.

  • Business Wire

    Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

    SAN FRANCISCO, May 31, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent

  • Business Wire

    Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

    SAN FRANCISCO, May 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.